Camp4 Therapeutics Income Statement (2023-2025) | CAMP

Income Statement Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.35M0.65M0.86M1.50M0.80M
Operating items
Research & Development 9.82M10.66M9.74M9.39M9.70M10.00M10.15M10.34M9.36M
Selling, General & Administrative 2.87M2.81M3.13M3.27M3.81M4.69M3.81M4.18M4.60M
Other Operating Expenses 0.49M
Operating Expenses 12.69M13.48M12.88M12.66M13.52M14.69M13.96M14.53M14.45M
Operating Income -12.34M-13.48M-12.88M-12.66M-13.52M-14.03M-13.10M-13.03M-13.65M
EBIT -12.34M-13.48M-12.88M-12.66M-13.52M-14.03M-13.10M-13.03M-13.65M
Non-operating items
Non Operating Investment Income -1.80M
Interest & Investment Income 0.69M0.57M0.40M0.23M0.09M0.61M0.59M0.45M0.42M
Other Non Operating Income 0.03M-0.14M-0.06M0.08M-0.01M-0.07M
Non Operating Income 0.64M0.49M0.42M-0.14M-0.06M0.76M0.67M0.44M-1.45M
Net income details
EBT -11.70M-12.99M-12.48M-12.43M-13.48M-13.28M-12.51M-12.57M-13.23M
Profit After Tax -11.70M-12.99M-12.45M-12.58M-13.48M-13.29M-12.43M-12.59M-15.10M
Income from Continuing Operations -11.70M-12.99M-12.48M-12.43M-13.48M-13.28M-12.51M-12.57M-13.23M
Consolidated Net Income -11.70M-12.99M-12.48M-12.43M-13.48M-13.28M-12.51M-12.57M-13.23M
Income towards Parent Company -11.70M-12.99M-12.48M-12.43M-13.48M-13.28M-12.51M-12.57M-13.23M
Net Income towards Common Stockholders -11.70M-12.99M-12.48M-12.43M-13.48M-13.28M-12.51M-12.57M-13.23M
Additional items
EPS (Basic) -29.21-30.18-26.57-26.00-24.19-2.83-0.62-0.62-0.55
EPS (Weighted Average and Diluted) -29.21-30.18-26.57-26.00-24.19-2.83-0.62-0.62-0.55
Shares Outstanding (Weighted Average) 0.40M0.39M0.47M0.48M0.56M4.69M20.15M20.16M27.27M
Shares Outstanding (Diluted Average) 0.40M0.39M0.47M0.48M0.56M4.69M20.15M20.16M27.27M
EBITDA -11.70M-12.99M-12.45M-12.58M-13.48M-13.28M-12.43M-12.59M-15.10M
Interest Expenses 0.05M0.08M0.06M-0.14M